Premium
Detection of sentinel lymph node in laparoscopic surgery for uterine cervical cancer using carbon nanoparticles
Author(s) -
Wang Yating,
Dan Zhao,
Yuan Guangwen,
Zhang Gongyi,
Liu Shuanghuan,
Zhang Yanan,
Li Bin
Publication year - 2020
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26100
Subject(s) - medicine , parametrial , sentinel lymph node , cervical cancer , lymph node , stage (stratigraphy) , laparoscopy , laparoscopic surgery , carbon nanoparticles , lymph , radiology , surgery , cancer , breast cancer , pathology , cervical carcinoma , paleontology , materials science , nanoparticle , biology , nanotechnology
Abstract Background and Objectives Carbon nanoparticles (CNPs) has been widely confirmed the efficiency in sentinel lymph node (SLN) mapping for various solid tumors. This study aims to explore the feasibility and effectiveness of CNPs during laparoscopic surgery for cervical cancer. Methods We analyzed 45 women with stage IB1‐IIA1 cervical cancer who underwent SLN mapping using CNPs during laparoscopic surgery. The effectiveness of CNPs was evaluated by the detection rate and accuracy parameters. Factors associated with SLN laterality and SLNs localizations were analyzed. Results The overall and bilateral detection rate was 93.3% (42/45) and 60.0% (27/45), respectively. Elevated body mass index was associated with decreased bilateral detection rate ( P = .015). A total of 225 SLNs were harvested, with a mean number of 5.0 ± 3.6. A total of 81.3% of SLNs were in expected localizations including external iliac (39.1%), internal iliac (25.8%), and obturator (16.4%) regions, while 18.7% in unusual localizations including common iliac (10.7%), parametrial (7.6%), and presarcal (0.4%) regions. None positive lymph node was found in non‐SLNs with a false‐negative rate of 0%. Conclusion Laparoscopic SLN mapping with CNPs appears to be simple and efficient for patients with early‐stage cervical cancer.